Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND (NCT03587805), a na phase 3 study. The primary outcome is Number of Adverse Events From Baseline Through the Last Treatment Visit (up to Week 268).

2. Clinical Question

The central question is descriptive: what adverse events were recorded while participants continued treatment in an extension setting? The registry identifies the primary outcome as the number of adverse events from Week 0 up to Week 268. It also lists secondary outcomes assessing Investigator’s Global Assessment scores of 0 (Clear) or 1 (Almost Clear), and EASI75 relative to baseline in the parent trial, at specified follow-up weeks.

Those questions concern observations over time among people entering an extension after earlier trials. They do not establish how outcomes would compare with a group assigned to another treatment or no treatment. The trial is listed as phase 3 and completed, with a primary completion date of 2024-07-03. The registry record’s brief summary states that the purpose was to evaluate long-term safety. The posted information should therefore be read chiefly as a record of safety monitoring and outcomes in this particular extension group, rather than as a controlled estimate of comparative treatment effects.

3. Trial Design

This was an open-label, single-arm, multi-centre, phase 3 long-term extension trial. Participants had atopic dermatitis and had participated in previous tralokinumab clinical trials. The registry lists 1672 enrolled participants. The trial is marked completed; the listed start date is 2018-03-18 and the primary completion date is 2024-07-03.

All subjects were assigned to the tralokinumab group in the registry description. The listed regimen was a subcutaneous loading dose at Week 0, followed by a subcutaneous maintenance dose from Week 2 up to Week 266. The length of treatment for each subject depended on when they entered, which parent trial they came from, and their country. This means participants did not necessarily share an identical period of exposure. The primary outcome timeframe extends from Week 0 through the last treatment visit, up to Week 268.

Open-label means that the treatment was not masked from participants or trial staff, according to the registry record. A single-group design has no concurrently assigned control group, and the allocation field is listed as not applicable. As a result, there is no randomized, like-for-like comparison within this trial. The design can describe outcomes observed among participants who entered the extension, but it cannot by itself distinguish treatment effects from changes over time, differences between participants, or other influences.

Because this is an extension of earlier trials, the study population is defined partly by prior trial participation. The registry does not report the specific entry criteria, the number of participants contributed by each parent trial, or a detailed account of how prior trial participation affected eligibility. Those details are not reported in the registry record. The record also does not describe a sample-size justification or provide a statistical analysis plan. The tables, plots, and planning illustrations on this page should be read as displays of the posted information or statistical illustrations, not as evidence that the trial was designed around a particular comparative analysis.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Adverse Events From Baseline Through the Last Treatment Visit (up to Week 268), measured over From Week 0 up to Week 268.

The primary endpoint is the number of adverse events recorded from baseline through the last treatment visit, with follow-up extending up to Week 268. It is a count outcome: the target is the number of events, rather than a score measuring disease severity or a comparison between treatment groups. The registry gives the timeframe as Week 0 up to Week 268, and lists the unit as events.

In general, counting adverse events is a way to summarize safety observations during treatment and follow-up. Counts can describe the volume of reported events, but they need careful interpretation. A total event count is not necessarily the same as the number of participants who experienced an event: one participant may experience more than one event. Counts also depend on how long participants are observed and on the rules used to identify, collect, and classify events.

Here, the registry’s primary endpoint title refers to adverse events, while the displayed safety summary separately reports the number of participants at risk and affected for serious and other adverse events. These are distinct summaries and should not be treated as interchangeable. The numerical primary endpoint result and details of its analysis are not reported in the registry record. Therefore, this page can explain what the endpoint was intended to measure, but cannot summarize its posted event-count result or its precision.

The endpoint is relevant to the stated purpose of evaluating long-term safety. However, a count collected in a single-group extension describes what was recorded in that group; it does not indicate how many events would have occurred under a different treatment or without treatment.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a single-group design show?

In general, a single-group study describes what was observed among participants receiving the study treatment. Here, the record describes an open-label, single-group extension of earlier tralokinumab trials. Since there is no concurrent comparison group, the analysis cannot directly estimate the difference between tralokinumab and another treatment under the same trial conditions. Changes or events observed during follow-up can be described, but comparisons with an unobserved alternative require assumptions the design does not test.

The open-label nature also means treatment was not masked. In general, awareness of treatment can affect reporting, follow-up behavior, or assessment, depending on the outcome and study procedures. The registry does not describe outcome-assessment procedures or how the study addressed potential effects of unmasked treatment. Those procedures are not reported in the registry record.

How should a count endpoint be understood?

The primary endpoint is the number of adverse events over the stated period, from Week 0 up to Week 268. In general, count outcomes record how many events occur, not merely whether a participant had at least one. Counts may vary because of both the number of people observed and the length of their observation. When follow-up duration differs, an analysis may account for exposure time, but the registry does not report whether or how that was done for the primary endpoint.

In general, count data can be more variable than a simple statistical model assumes, a feature often called over-dispersion. If over-dispersion is present, methods that allow for it may give more appropriate uncertainty estimates than methods assuming a narrower count distribution. This is general statistical context, not a description of the analysis used. The registry record does not report a model, distributional assumption, or uncertainty interval for the primary endpoint. It also does not provide the numerical primary endpoint result.

It is important to keep the endpoint count separate from the safety summary. The summary reports how many participants were affected by serious and other adverse events, while the endpoint title asks for the number of events. One participant can contribute multiple events, so the two summaries need not match. The record does not give enough information to reconstruct total event counts from the affected-participant figures.

What do the displayed safety counts mean?

The serious and other adverse-event summaries are descriptive. The registry lists 1672 at risk for each category, 151 affected by serious adverse events, and 924 affected by other adverse events; it also lists 1 death. In general, an affected-participant count indicates participants recorded with at least one event in that category, rather than a complete accounting of every event occurrence. The precise counting and classification conventions are not described in the registry record.

The serious-event terms and percentages are also descriptive registry entries. They show which terms are listed and their displayed percentages, but do not provide a comparison group, event-level chronology, or an analysis of causal attribution. In general, a percentage without a comparative design does not estimate a treatment-attributable excess. Nor does a listed term establish that all events under that term had the same clinical context.

What can the planning illustrations tell readers?

In general, sample-size calculations are planning tools: they illustrate the number of participants that might be needed under stated assumptions to detect a specified effect in a comparison. The planning illustrations use assumptions of a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and an effect defined as a stated fraction of the observed effect. For time-to-event tables, the illustration concerns total events; other illustrations concern participants per arm.

These illustrations are not the design of this extension trial, which was single-group and had no randomized two-arm comparison. They are not observed power and do not show what the trial established. The registry record does not report a trial-specific sample-size justification, and the planning assumptions should not be mistaken for a documented protocol analysis plan.

More broadly, precision is often summarized with a confidence interval. In general, a confidence interval shows a range of values compatible with the data and analysis under the method’s assumptions; wider intervals indicate less precision. The registry record does not report a confidence interval or other uncertainty measure for the primary endpoint. Because no primary result or analysis is listed, readers cannot assess the endpoint’s precision from the registry information.

Which analyses are documented?

The record lists no analyses. It names the primary count endpoint and secondary outcomes, but does not report an analysis population, model, handling of repeated observations, missing-data method, or adjustment for multiple comparisons. Those features are not reported in the registry record. Statistical methods are general explanations and should not be taken as methods used in this trial.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary adverse-event count outcome and secondary outcomes for Investigator’s Global Assessment and EASI75 at several follow-up weeks. When a study evaluates multiple outcomes or repeated time points, there are more opportunities for an apparently notable result to arise by chance. In general, a statistical plan may address this multiplicity through a prespecified testing sequence, an adjustment, or a clearly descriptive interpretation. The registry record does not report a multiplicity strategy.

The record lists no analyses. It does not report whether the secondary outcomes were analyzed as repeated measures, assessed separately at each time point, or included in a formal testing hierarchy. It also does not report p-values or uncertainty estimates for those outcomes. The listed endpoint schedule alone is not enough to infer how the investigators analyzed the data or interpreted any findings.

Missing-data handling is not reported in the registry record. The record does not explain how missing visits, withdrawal, incomplete outcome assessments, or differing follow-up duration were handled. This matters in an extension study because the treatment length for each participant depended on entry timing, parent trial, and country. In general, conclusions from longitudinal outcomes can depend on who remains under observation and how missing measurements are addressed.

The analysis populations are also not reported. The registry does not say whether analyses included all enrolled participants, only participants who received treatment, or a defined subset with available observations. The enrollment and at-risk counts appear in the safety summary, but they do not by themselves establish the analysis population for the primary or secondary outcomes. Without these details, readers should avoid assuming that every enrolled participant contributed to every outcome at every visit.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: atopic dermatitis (0.7%), covid-19 (0.3%), anaphylactic reaction (0.2%), coronary artery stenosis (0.2%), cataract (0.2%).

The safety summary lists 1672 participants at risk for serious adverse events and 151 affected. For other adverse events, it lists 1672 at risk and 924 affected. The registry also records 1 death. These are descriptive figures for the tralokinumab, all-subjects group. They are not a comparison between treatments, and they do not show what would have occurred in a control group.

The registry lists these serious-event terms and percentages: Atopic dermatitis, 0.7%; Covid-19, 0.3%; Anaphylactic reaction, 0.2%; Coronary artery stenosis, 0.2%; Cataract, 0.2%; and Eczema herpeticum, 0.2%. These should be read as the terms and percentages displayed in the record, not as evidence that tralokinumab caused the events. The record does not provide event-level details or a comparative attribution analysis.

In general, a serious adverse event is a safety classification, while an adverse event is a broader category. A participant-level affected count does not equal the total number of event occurrences; a participant may experience more than one event. The primary endpoint’s total event count is not reported in the registry record, so it cannot be inferred from these affected-participant figures.

12. What the Result Does, and Does Not, Mean

The record supports a descriptive account of a long-term extension study in which participants with atopic dermatitis who had taken part in previous tralokinumab trials received tralokinumab. It reports enrollment of 1672, a single-group open-label design, a primary outcome defined as the number of adverse events through the last treatment visit up to Week 268, and selected safety counts and terms. This information helps characterize what the registry recorded for the study and its stated focus on long-term safety.

It does not establish how those observations compare with outcomes under another treatment or no treatment. The trial has no concurrent control group and no randomized comparison, so observed events cannot be attributed to tralokinumab by comparison with an otherwise similar group. The record does not report a causal analysis. The fact that an event occurred during the study is not, by itself, proof that treatment caused it.

The record also does not provide the numerical result for the primary count endpoint, its uncertainty, or its analysis method. The safety summary’s affected-participant counts are not a substitute for the endpoint’s total event count. Similarly, the secondary outcome titles and follow-up weeks do not show whether participants improved, worsened, or remained unchanged; numerical results are not reported.

In general, an extension cohort can contribute information about outcomes observed during continued treatment, but interpretation depends on participant selection, follow-up, event ascertainment, and analysis. The registry identifies participants as coming from earlier trials and notes that treatment duration depended on entry timing, parent trial, and country. It does not provide detailed results addressing differences in exposure or follow-up.

Accordingly, the posted information should be understood as a registry description and a limited set of descriptive safety figures, not as a comparative estimate of benefit or harm. The trial’s completed status and phase do not supply missing outcome results or resolve the limitations of its single-group design.

13. Why This Trial Matters Statistically

This trial matters statistically because it illustrates the difference between describing events during long-term treatment and estimating a treatment effect. The extension enrolled 1672 participants and followed a regimen that could continue from Week 0 through maintenance treatment up to Week 266, with the primary endpoint timeframe extending up to Week 268. The period of observation was not uniform by design: the registry says treatment length depended on entry timing, parent trial, and country. That makes exposure and follow-up important parts of interpreting any count outcome.

The primary endpoint is an event count, while the displayed safety summary reports affected-participant counts. Those quantities answer different questions. A count of events can include repeated events in a participant; an affected-participant count captures participants with events. Statistical reporting is clearest when the endpoint definition, denominator, follow-up, analysis, and uncertainty are all explicit. The registry does not report the numerical primary endpoint result or the analysis details needed to connect these pieces.

The design also makes the limits of causal interpretation visible. A single-group extension can describe what happened in its enrolled cohort, but it cannot provide the randomized counterfactual that a concurrent comparison group would offer. This distinction remains important even when a trial is phase 3, completed, and has a sizable enrollment.

Finally, the record lists several secondary outcomes across multiple weeks. This raises general questions about multiplicity, missing observations, and analysis populations, but the registry does not report how these were handled. The tables, plots, and planning illustrations can help readers engage with displayed information and statistical concepts; they should not be mistaken for analyses absent from the registry record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is the lack of a concurrent comparator. This open-label, single-group extension cannot estimate a randomized treatment contrast, and observed events cannot be separated from background risk or other influences using the trial design alone. The population also consists of people who participated in previous tralokinumab trials, so the registry description does not establish how representative they are of people with atopic dermatitis generally.

Treatment and observation duration varied according to entry timing, parent trial, and country. The registry does not report participant-level exposure time, the distribution of follow-up, or an analysis accounting for different time under observation. Raw counts can be difficult to compare when observation time differs. The primary endpoint’s numerical result and uncertainty are not reported in the registry record.

The safety summary gives affected-participant counts and selected serious-event terms, but does not provide detailed event-level information, case narratives, or a comparative assessment of causality. The count of participants affected is not the total number of events. The registry also records 1 death but does not provide information to interpret its circumstances or relationship to treatment.

Further limitations include the absence of reported analysis populations, missing-data methods, multiplicity procedures, and a detailed statistical analysis plan. The registry lists secondary outcomes and their assessment weeks but does not report numerical outcome findings. The eligibility criteria, contributions from individual parent trials, and rationale for enrollment are not reported in the registry record. These omissions constrain assessment of selection, precision, and the robustness of any outcome interpretation.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND — NCT03587805.
• Registry record last updated 2025-03-11; status last verified 2024-12.
• Results first posted 2025-01-16.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes NCT03587805, titled ECZTEND, as a completed phase 3, open-label, single-group, multi-centre extension trial of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab trials. Enrollment was 1672. The listed start date is 2018-03-18 and the primary completion date is 2024-07-03.

The primary outcome is the number of adverse events from Week 0 through the last treatment visit, up to Week 268. The regimen began with a subcutaneous loading dose at Week 0 and continued with maintenance dosing from Week 2 up to Week 266; individual treatment length depended on entry timing, parent trial, and country.

The safety summary lists 151 participants affected by serious adverse events, 924 affected by other adverse events, and 1 death among 1672 at risk. The numerical primary endpoint result, outcome analyses, analysis populations, missing-data methods, and multiplicity procedures are not reported in the registry record. With no concurrent comparator, the posted figures are descriptive rather than randomized estimates of comparative effects.